Massimo Di Maio, Associate Professor of Medical Oncology at the Department of Oncology at the University of Turin, shared a post on LinkedIn about a recent article he and colleagues authored:
“Quality of life outcomes are extremely relevant to the interpretation of a clinical trial, particularly in clinical situations where disease symptoms and treatment toxicity have a significant impact.
This is even more true in academic research, which should aim to optimize therapeutic decisions in clinical practice.
Thanks to Eleonora Cristarella, Margherita Ambrosini, Filippo Pietrantonio, Giovanni Randon, and all the coauthors, for the opportunity of contributing to the QoL analysis of the ARMANI phase 3 trial.”
Title: Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial
Authors: Eleonora Cristarella, Margherita Ambrosini, Massimo Di Maio, Sara Lonardi, Ferdinando De Vita, Samantha Di Donato, Elisa Giommoni, Andrea Spallanzani, Alessandro Bittoni, Claudio Chini, Antonia Strippoli, Tiziana Pia Latiano, Oronzo Brunetti, Stefano Tamberi, Giovanni Gerardo Cardellino, Daniele Spada, Lorenzo Fornaro, Sara Alessandrini, Filippo Pietrantonio, Giovanni Randon
Read the Full Article in the European Journal of Cancer.
More posts featuring Massimo Di Maio on OncoDaily.